Narwhal Capital Management Buys New Position in Zoetis Inc. $ZTS

Key Points

• Narwhal Capital Management has acquired a new stake of 4,215 shares in Zoetis Inc. valued at approximately $657,000 during the 2nd quarter.
• Zoetis recently reported an EPS of $1.76 for the last quarter, exceeding analysts' expectations, with revenue reaching $2.46 billion.
• Brokerages have issued mixed ratings on Zoetis, with five analysts giving a Buy rating and five others a Hold rating, resulting in a consensus rating of "Moderate Buy" and a target price of $200.88.

Narwhal Capital Management bought a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,215 shares of the company's stock, valued at approximately $657,000.

Other hedge funds also recently added to or reduced their stakes in the company. Nova Wealth Management Inc. acquired a new position in Zoetis during the 1st quarter valued at about $25,000. 1248 Management LLC acquired a new position in Zoetis during the 1st quarter valued at about $27,000. Saudi Central Bank acquired a new position in Zoetis during the 1st quarter valued at about $29,000. REAP Financial Group LLC increased its position in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company's stock valued at $31,000 after buying an additional 131 shares in the last quarter. Finally, Cornerstone Planning Group LLC increased its position in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after buying an additional 88 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ZTS. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Zoetis in a research report on Wednesday. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Argus reiterated a "buy" rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Five equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Stock Up 0.6%

Shares of ZTS opened at $143.61 on Thursday. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $196.55. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $63.65 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 2.29 and a beta of 0.90. The stock's 50-day moving average price is $149.41 and its 200-day moving average price is $154.74.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the business earned $1.56 earnings per share. The company's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.